Practical pituitary pathology: What does the pathologist need to know?

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 8, 2008, Pages 1231-1240

  Asa, Sylvia L ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; FOLLITROPIN; GONADOTROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; PROLACTIN; THYROTROPIN;

ADENOHYPOPHYSIS DISEASE; AUTOPSY; CLINICAL PRACTICE; CRANIOPHARYNGIOMA; CYST; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; GERM CELL TUMOR; HISTOLOGY; HORMONE RELEASE; HUMAN; HYPERPLASIA; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS DISEASE; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; PATHOLOGIST; PROGNOSIS; REVIEW; TUMOR CLASSIFICATION;

ADENOMA; AUTOPSY; BIOLOGICAL MARKERS; CELL PROLIFERATION; COLORING AGENTS; EOSINE YELLOWISH-(YS); FLUORESCENT DYES; HEMATOXYLIN; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON; PITUITARY DISEASES; PITUITARY GLAND; PITUITARY GLAND, ANTERIOR; PITUITARY HORMONES; PITUITARY NEOPLASMS; PROGNOSIS; STAINING AND LABELING;

EID: 49449100984     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Asa SL. Tumors of the Pituitary Gland. Washington, DC: Armed Forces Institute of Pathology; 1998. Atlas of Tumor Pathology ; 3rd series, fascicle 22.
2. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours.
3. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613-619.
4. Shin JL, Asa SL, Woodhouse LJ, Smyth HS, Ezzat S. Cystic lesions of the pituitary: clinicopathological features distinguishing craniopharyngioma, Rathke's cleft cyst, and arachnoid cyst. J Clin Endocrinol Metab. 1999;84:3972-3982.
5. Cheung CC, Ezzat S, Smyth HS, Asa SL. The spectrum and significance of primary hypophysitis. J Clin Endocrinol Metab. 2001;86:1048-1053.
6. Puchner MJA, Lüdecke DK, Saeger W, Riedel M, Asa SL. Gangliocytomas of the sellar region - a review. Exper Clin Endocrinol. 1995;103:129-149.
7. Sarubi JC, Bei H, Adams EF, et al. Clonal composition of human adamantinomatous craniopharyngiomas and somatic mutation analyses of the patched (PTCH), Gsα and Gi2α genes. Neurosci Lett. 2001;310(1):5-8.
8. Sekine S, Shibata T, Kokubu A, et al. Craniopharyngiomas of adamantinomatous type harbor β-Catenin gene mutations. Am J Pathol. 2002;161:1997-2001.
9. Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg. 1985;63:155-167.
10. Samaratunga H, Perry-Keene D, Apel RL. Primary lymphoma of the pituitary gland: a neoplasm of acquired MALT? Endocr Pathol. 1997;8:335-341.
11. Kuhn D, Buchfelder M, Brabletz T, Paulus W. Intrasellar malignant lymphoma developing within pituitary adenoma. Acta Neuropathol (Berl). 1999;97:311-316.
12. Landman RE, Wardlaw SL, McConnell RJ, Khandji AG, Bruce JN, Freda PU. Pituitary lymphoma presenting as fever of unknown origin. J Clin Endocrinol Metab. 2001;86:1470-1476.
13. Roessmann U, Kaufman B, Friede RL. Metastatic lesions in the sella turcica and pituitary gland. Cancer. 1970;25:478-480.
14. Kovacs K. Metastatic cancer of the pituitary gland. Oncology. 1973;27:533-542.
15. McCormick PC, Post KD, Kandji AD, Hays AP. Metastatic carcinoma to the pituitary gland. Br J Neurosurg. 1989;3:71-79.
16. Fassett DR, Couldwell WT. Metastases to the pituitary gland. Neurosurg Focus. 2004;16(4):E8.
17. Branch CL Jr, Laws ER Jr. Metastatic tumors of the sella turcica masquerading as primary pituitary tumors. J Clin Endocrinol Metab. 1987;65:469-474.
18. Khalil A, Kovacs K, Sima AAF, Burrow GN, Horvath E. Pituitary thyrotroph hyperplasia mimicking prolactin-secreting adenoma. J Endocrinol Invest. 1984;7:399-404.
19. Kubota T, Hayashi M, Kabuto M, et al. Corticotroph cell hyperplasia in a patient with Addison disease: case report. Surg Neurol. 1992;37:441-447.
20. Sano T, Asa SL, Kovacs K. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev. 1988;9:357-373.
21. Ezzat S, Asa SL, Stefaneanu L, et al. Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid. J Clin Endocrinol Metab. 1994;78:555-560.
22. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev. 1998;19:798-827.
23. Asa SL, Ezzat S. Molecular basis of pituitary development and cytogenesis. Front Horm Res. 2004;32:1-19.
24. Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP. Cell type-specific expression of the pituitary transcription activator Pit-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab. 1993;77:1275-1280.
25. Friend KE, Chiou Y-K, Laws ER Jr, Lopes MBS, Shupnik MA. Pit-1 messenger ribonucleic acid is differentially expressed in human pituitary adenomas. J Clin Endocrinol Metab. 1993;77:1281-1286.
26. Friend KE, Chiou YK, Lopes MBS, Laws ER Jr, Hughes KM, Shupnik MA. Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas. J Clin Endocrinol Metab. 1994;78:1497-1504.
27. Zafar M, Ezzat S, Ramyar L, Pan N, Smyth HS, Asa SL. Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab. 1995;80:3621-3627.
28. Asa SL, Bamberger A-M, Cao B, Wong M, Parker KL, Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab. 1996;81:2165-2170.
29. Lamolet B, Pulichino AM, Lamonerie T, et al. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 2001;104:849-859.
30. Lamonerie T, Tremblay JJ, Lanctot C, Therrien M, Gauthier Y, Drouin J. Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Genes Dev. 1996;10:1284-1295.
31. Poulin G, Turgeon B, Drouin J. NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol. 1997;17:6673-6682.
32. Ingraham HA, Chen R, Mangalam HJ, et al. A tissue-specific transcription factor containing a homeodomain specifies a pituitary phenotype. Cell. 1988;55:519-529.
33. Mangalam HJ, Albert VR, Ingraham HA, et al. A pituitary POU domain protein, Pit-1, activates both growth hormone and prolactin promoters transcriptionally. Genes Dev. 1989;3:946-958.
34. Li S, Crenshaw EB III, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature. 1990;347:528-533.
35. Ingraham HA, Albert VR, Chen R, et al. A family of POU-domain and Pit-1 tissue-specific transcription factors in pituitary and neuroendocrine development. Annu Rev Physiol. 1990;52:773-791.
36. Rosenfeld MG. POU-domain transcription factors: pou-er-ful developmental regulators. Genes Dev. 1991;5:897-907.
37. Yan G, Pan WT, Bancroft C. Thyrotropin-releasing hormone action on the prolactin promotor is mediated by the POU protein Pit-1. Mol Endocrinol. 1991;5:535-541.
38. Day RN, Koike S, Sakai M, Muramatsu M, Maurer RA. Both Pit-1 and the estrogen receptor are required for estrogen responsiveness of the rat prolactin gene. Mol Endocrinol. 1990;4:1964-1971.
39. Drolet DW, Scully KM, Simmons DM, et al. TEF, a transcription factor expressed specifically in the anterior pituitary during embryogenesis, defines a new class of leucine zipper proteins. Genes Dev. 1991;5:1739-1753.
40. Scully KM, Rosenfeld MG. Pituitary development: regulatory codes in mammalian organogenesis. Science. 2002;295:2231-2235.
41. Frawley LS, Boockfor FR. Mammosomatotropes: presence and functions in normal and neoplastic pituitary tissue. Endocr Rev. 1991;12:337-355.
42. Horvath E, Lloyd RV, Kovacs K. Propylthiouracil-induced hypothyroidism results in reversible transdifferentiation of somatotrophs into thyroidectomy cells: a morphologic study of the rat pituitary including immunoelectron microscopy. Lab Invest. 1990;63:511-520.
43. Trouillas J, Guigard MP, Fonlupt P, Souchier C, Girod C. Mapping of corticotropic cells in the normal human pituitary. J Histochem Cytochem. 1996;44:473-479.
44. McNicol AM. Patterns of corticotropic cells in the adult human pituitary in Cushing's disease. Diag Histopathol. 1981;4:335-341.
45. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol. 1995;133:686-690.
46. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol. Metab. 2005;90:6290-6295.
47. Asa SL, DiGiovanni R, Jiang J, et al. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res. 2007;67:7505-7511.
48. Labat-Moleur F, Trouillas J, Seret-Begue D, Kujas M, Delisle M-B, Ronin C. Evaluation of 29 monoclonal and polyclonal antibodies used in the diagnosis of pituitary adenomas: a collaborative study from pathologists of the Club Français de l'Hypophyse. Pathol Res Pract. 1991;187:534-538.
49. Jastania RA, Alsaad KO, Al Shraim M, Kovacs K, Asa SL. Double adenomas of the pituitary: transcription factors Pit-1, T-pit, and SF-1 identify cytogenesis and differentiation. Endocr Pathol. 2005;16:187-194.
50. Kovacs K, Horvath E. Tumors of the Pituitary Gland. Washington, DC: Armed Forces Institute of Pathology; 1986. Atlas of Tumor Pathology; 2nd series, fascicle 21.
51. Knosp E, Kitz K, Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery. 1989;25:927-930.
52. Amar AP, Hinton DR, Krieger MD, Weiss MH. Invasive pituitary adenomas: significance of proliferation parameters. Pituitary. 1999;2(2):117-122.
53. Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:99-107.
54. Vidal S, Kovacs K, Horvath E, et al. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol. 2002;15:1205-1212.
55. Vidal S, Kovacs K, Bell D, Horvath E, Scheithauer BW, Lloyd RV. Cyclooxygenase-2 expression in human pituitary tumors. Cancer. 2003;97:2814-2821.
56. Yoshino A, Katayama Y, Fukushima T, et al. Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence. J Neurooncol. 2003;63:155-162.
57. Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res. 2003;63:2251-2255.